StockNews.com Begins Coverage on ProPhase Labs (NASDAQ:PRPH)

StockNews.com initiated coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

ProPhase Labs Trading Up 0.7 %

ProPhase Labs stock opened at $0.26 on Friday. ProPhase Labs has a one year low of $0.22 and a one year high of $7.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The firm has a 50-day moving average of $0.59 and a 200-day moving average of $1.61. The company has a market cap of $6.27 million, a price-to-earnings ratio of -0.21 and a beta of -0.37.

Institutional Trading of ProPhase Labs

Several institutional investors and hedge funds have recently bought and sold shares of PRPH. Geode Capital Management LLC raised its position in shares of ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares in the last quarter. HighTower Advisors LLC grew its position in ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares during the last quarter. SVB Wealth LLC bought a new position in ProPhase Labs in the 4th quarter valued at approximately $36,000. Finally, Sheets Smith Wealth Management bought a new stake in ProPhase Labs during the 4th quarter worth $158,000. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.